Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
1 other identifier
expanded_access
N/A
1 country
7
Brief Summary
This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 5, 2022
CompletedFirst Posted
Study publicly available on registry
October 10, 2022
CompletedMay 6, 2026
May 1, 2026
October 5, 2022
May 5, 2026
Conditions
Keywords
Interventions
An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
Eligibility Criteria
You may qualify if:
- Participants must have completed predicate study protocol requirements, including prior treatment duration and follow-up.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Agenus Inc.lead
Study Sites (7)
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
Arizona Oncology Associates
Tucson, Arizona, 85711, United States
Hoag Gynecologic Oncology
Newport Beach, California, 92663, United States
University of California, San Francisco Medical Center
San Francisco, California, 94158, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43212, United States
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, 02905, United States
Texas Oncology
Flower Mound, Texas, 75028, United States
MeSH Terms
Conditions
Interventions
Study Officials
- STUDY DIRECTOR
Medical Director
Agenus Inc.
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 5, 2022
First Posted
October 10, 2022
Last Updated
May 6, 2026
Record last verified: 2026-05